Randomised Placebo Controlled Trial of Celecoxib for Acute Burn Inflammation and Fever

Fiona Stanley Hospital0 个研究点目标入组 150 人开始时间: 2018年5月2日最近更新: 2018年11月19日

适应症

试验速览

暂无简介。

•Less than 48 hours from admission to the burns unit with acute burn injury
•Outpatient booked for day of surgery admission for management of acute burn injury

•i. Regular NSAID use prior to injury (including any dose aspirin)
•ii. Major burn with TBSA>20% or requiring admission to the intensive care unit
•iii. Enrolment not considered in the patient’s best interest
•iv. Previously enrolled in the CABIN Fever study
•v. Participating in a competing interventional study
•vi. Pregnancy or breast feeding
•vii. NSAID or sulphonamide allergy
•viii. Renal dysfunction (eGFR <60)
•ix. Angina, myocardial infarction, heart failure (NYHA class II or greater: ordinary physical activity results in fatigue, palpitations or dyspnoea)
•x. Previous history of peripheral arterial disease or stroke
•xi. Current use of angiotensin converting enzyme inhibitor or angiotensin II receptor blocker
•xii. Suspected or confirmed hepatic cirrhosis, portal hypertension or variceal bleeding
•xiii. Current ALT 3x upper limit of normal or Bilirubin 2x upper limit of normal
•xiv. Previous history of gastric ulcer or gastrointestinal bleeding
•xv. Current systemic corticosteroid use
•xvi. Suspected or confirmed haemophilia
•xvii. Current use of anticoagulant medications including warfarin, new oral anticoagulants (NOACs) such as apixaban, dabigatran and rivaroxaban and treatment dose heparin
•xviii. Suspected or confirmed thrombophilia or previous history of thromboembolism

发起方